FIELD: medicine.
SUBSTANCE: method involves administering Nateglynid and Glytazon in pharmaceutically permissible carrier. The combination is optionally administered as combined preparation or pharmaceutical composition. The pharmaceutical composition (the second version) has Nateglynid and Methformin as the second anti-diabetic agent enclosed into the pharmaceutical carrier.
EFFECT: enhanced effectiveness of synergetic preparations action upon diabetes II; prolonged therapeutic drug action time; postponed insulin administration.
13 cl, 1 tbl
Authors
Dates
2006-07-27—Published
2000-09-15—Filed